Category Archives: RCC

AGILE Trial: Frontline Axitinib Versus Sorafenib in mRCC

As part of their Peer Exchange Series, onclive.com presents a discussion of the AGILE Trial by one of the collaborators, Thomas Hutson, and moderated by Daniel J. George from the Duke Cancer Institute in the Clinical Developments in Renal Cell Carcinoma section.

Published online July 22, 2013.